Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Beltran Lab
Explore this Website
Home
About Us
Toggle About Us menu options
Contact Us
Job Opportunities
Videos
Affiliations
Research
Lab Team
News
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Affiliations
Research
Lab Team
News
Publications
Home
Publications
Publications
Found 69 results
Author
Title
Type
Year
Filters:
About-us
is
contact-us
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
A
Akamatsu S
,
Wyatt AW
,
Lin D
,
Lysakowski S
,
Zhang F
,
Kim S
,
Tse C
,
Wang K
,
Mo F
,
Haegert A
et al.
. 2015.
The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.
.
Cell Rep. 12(6):922-36.
Armenia J
,
Wankowicz SAM
,
Liu D
,
Gao J
,
Kundra R
,
Reznik E
,
Chatila WK
,
Chakravarty D
,
G Han C
,
Coleman I
et al.
. 2018.
The long tail of oncogenic drivers in prostate cancer.
.
Nat Genet. 50(5):645-651.
Attard G
,
Beltran H
. 2015.
Prioritizing precision medicine for prostate cancer.
.
Ann Oncol. 26(6):1041-2.
B
Baca SC
,
Prandi D
,
Lawrence MS
,
Mosquera JMiguel
,
Romanel A
,
Drier Y
,
Park K
,
Kitabayashi N
,
MacDonald TY
,
Ghandi M
et al.
. 2013.
Punctuated evolution of prostate cancer genomes.
.
Cell. 153(3):666-77.
Beltran H
,
Wyatt AW
,
Chedgy E
,
Donoghue A
,
Annala M
,
Warner E
,
Beja K
,
Sigouros M
,
Mo F
,
Fazli L
et al.
. 2017.
Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
.
Clin Cancer Res.
Beltran H
,
Tagawa ST
,
Park K
,
Macdonald T
,
Milowsky MI
,
Mosquera JMiguel
,
Rubin MA
,
Nanus DM
. 2012.
Challenges in recognizing treatment-related neuroendocrine prostate cancer.
.
J Clin Oncol. 30(36):e386-9.
Beltran H
,
Rickman DS
,
Park K
,
Chae SS
,
Sboner A
,
MacDonald TY
,
Wang Y
,
Sheikh KL
,
Terry S
,
Tagawa ST
et al.
. 2011.
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
.
Cancer Discovery. 1(6):487-95.
Beltran H
. 2016.
Update on the biology and management of neuroendocrine prostate cancer.
.
Clin Adv Hematol Oncol. 14(7):513-5.
Beltran H
,
Beer TM
,
Carducci MA
,
de Bono J
,
Gleave M
,
Hussain M
,
Kelly WK
,
Saad F
,
Sternberg C
,
Tagawa ST
et al.
. 2011.
New therapies for castration-resistant prostate cancer: efficacy and safety.
.
Eur Urol. 60(2):279-90.
Beltran H
,
Oromendia C
,
Danila DC
,
Montgomery B
,
Hoimes C
,
Szmulewitz RZ
,
Vaishampayan U
,
Armstrong AJ
,
Stein M
,
Pinski J
et al.
. 2018.
A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers.
.
Clin Cancer Res.
Beltran H
,
Prandi D
,
Mosquera JM
,
Benelli M
,
Puca L
,
Cyrta J
,
Marotz C
,
Giannopolou E
,
Chakravarthi BV
,
Varambally S
et al.
. 2016.
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
.
Nat Med. 3(22):298-305.
Beltran H
. 2013.
DNA mismatch repair in prostate cancer.
.
J Clin Oncol. 31(14):1782-4.
Beltran H
,
Jendrisak A
,
Landers M
,
Mosquera JM
,
Kossai M
,
Louw J
,
Krupa R
,
Graf RP
,
Schreiber NA
,
Nanus DM
et al.
. 2016.
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.
.
Clin Cancer Res. 6(22)
Beltran H
. 2014.
The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential.
.
Mol Cancer Res. 12(6):815-22.
Beltran H
,
Park K
,
Tagawa ST
,
Yelensky R
,
Lipson D
,
Frampton G
,
Stephens PJ
,
Cronin MT
,
Nanus DM
,
Mosquera JMiguel
et al.
. 2012.
Identifying cancer mutations in neuroendocrine prostate cancer (NEPC) through massively parallel DNA sequencing of formalin-fixed paraffin-embedded (FFPE) tissue.
.
J Clin Oncol. 30(5_suppl):110.
Beltran H
,
Tomlins S
,
Aparicio A
,
Arora V
,
Rickman D
,
Ayala G
,
Huang J
,
True L
,
Gleave ME
,
Soule H
et al.
. 2014.
Aggressive variants of castration-resistant prostate cancer.
.
Clin Cancer Res. 20(11):2846-50.
Beltran H
,
Tagawa ST
,
Park K
,
MacDonald T
,
Milowsky MI
,
Mosquera JM
,
Rubin MA
,
Nanus DM
. 2012.
Challenges in recognizing treatment-related neuroendocrine prostate cancer.
.
J Clin Oncol. 30(36):386-9.
Beltran H
,
Kaur G
,
de España CGarcías
,
Tagawa ST
. 2014.
Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib.
.
Asian J Androl. 16(4):568-9.
Beltran H
,
Park K
,
Tagawa ST
,
Macdonald T
,
Nanus DM
,
Mosquera JMiguel
,
Rubin MA
. 2012.
Association of concurrent AURKA and MYCN amplification in primary prostate adenocarcinoma with the development of lethal neuroendocrine prostate cancer (NEPC).
.
J Clin Oncol. 30(5_suppl):120.
Beltran H
,
Yelensky R
,
Frampton GM
,
Park K
,
,
MacDonald TY
,
Jarosz M
,
Lipson D
,
Tagawa ST
,
Nanus DM
et al.
. 2013.
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
.
Eur Urol. 63(5):920-6.
Beltran H
,
Rubin MA
. 2013.
New strategies in prostate cancer: translating genomics into the clinic.
.
Clin Cancer Res. 19(3):517-23.
Beltran H
,
Eng K
,
Mosquera JMiguel
,
Sigaras A
,
Romanel A
,
Rennert H
,
Kossai M
,
Pauli C
,
Faltas B
,
Fontugne J
et al.
. 2015.
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
.
JAMA Oncol. 1(4):466-74.
Beltran H
,
Antonarakis ES
,
Morris MJ
,
Attard G
. 2016.
Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.
.
Am Soc Clin Oncol Educ Book. (35):131-41.
Beltran H
,
Demichelis F
. 2015.
Prostate cancer: Intrapatient heterogeneity in prostate cancer.
.
Nat Rev Urol. 12(8):430-1.
Bishop JL
,
Thaper D
,
Vahid S
,
Davies A
,
Ketola K
,
Kuruma H
,
Jama R
,
Nip KMun
,
Angeles A
,
Johnson F
et al.
. 2017.
The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
.
Cancer Discov. 7(1):54-71.
1
(current)
2
3
next ›
last »